Were Analysts Bearish Exact Sciences Corporation (NASDAQ:EXAS) This Week?

Exact Sciences Corporation (NASDAQ:EXAS) Logo
Investors sentiment decreased to 1.26 in Q2 2019. Its down 0.03, from 1.29 in 2019Q1. It turned negative, as 31 investors sold Exact Sciences Corporation shares while 113 reduced holdings. 76 funds opened positions while 106 raised stakes. 108.62 million shares or 14.41% less from 126.90 million shares in 2019Q1 were reported.
Baystate Wealth Mngmt Ltd Limited Liability Company holds 0% in Exact Sciences Corporation (NASDAQ:EXAS) or 60 shares. Enterprise Serv accumulated 11 shares. Bailard Incorporated invested in 4,200 shares or 0.03% of the stock. C Group Incorporated Holdings A S reported 178,932 shares or 0.26% of all its holdings. Cubist Systematic Strategies Lc holds 0.2% or 93,071 shares in its portfolio. Gulf Intl Bancshares (Uk) Ltd invested in 0.06% or 32,050 shares. Td Asset accumulated 0.02% or 125,190 shares. Loring Wolcott And Coolidge Fiduciary Advisors Llp Ma has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Horseman Capital Management Ltd holds 0.75% in Exact Sciences Corporation (NASDAQ:EXAS) or 10,000 shares. Geode Capital Management Limited Company holds 0.04% in Exact Sciences Corporation (NASDAQ:EXAS) or 1.35 million shares. Sectoral Asset Mngmt invested 0.54% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Point72 Asset Mngmt L P stated it has 0.07% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Ftb Inc, a Tennessee-based fund reported 238 shares. Fisher Asset Mgmt Ltd Liability Company reported 0.01% stake. State Board Of Administration Of Florida Retirement Systems invested in 170,288 shares or 0.05% of the stock.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 3 analysts covering EXACT Sciences (NASDAQ:EXAS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. EXACT Sciences has $14300 highest and $11000 lowest target. $124.33’s average target is 16.51% above currents $106.71 stock price. EXACT Sciences had 6 analyst reports since March 15, 2019 according to SRatingsIntel. The company was maintained on Wednesday, May 1 by UBS. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Tuesday, April 16 by UBS. UBS maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Thursday, August 1. UBS has “Buy” rating and $14300 target. Goldman Sachs maintained Exact Sciences Corporation (NASDAQ:EXAS) on Friday, April 12 with “Buy” rating. The firm has “Buy” rating given on Wednesday, May 1 by Canaccord Genuity. Below is a list of Exact Sciences Corporation (NASDAQ:EXAS) latest ratings and price target changes.

01/08/2019 Broker: UBS Rating: Buy Old Target: $120.0000 New Target: $143.0000 Maintain
01/05/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $115.0000 New Target: $120.0000 Maintain
01/05/2019 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $100.0000 New Target: $110.0000 Maintain
16/04/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $109 New Target: $115 Maintain
12/04/2019 Broker: Goldman Sachs Old Rating: Buy New Rating: Buy New Target: $120 Maintain
15/03/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.82% or $1.98 during the last trading session, reaching $106.71. About 1.03M shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 100.54% since September 13, 2018 and is uptrending. It has outperformed by 100.54% the S&P500.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $13.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Nasdaq.com which released: “Why Exact Sciences Is Sinking and Genomic Health Is Rising – Nasdaq” on July 29, 2019, also Nasdaq.com with their article: “Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline – Nasdaq” published on April 23, 2019, Nasdaq.com published: “EXACT Sciences is Now Oversold (EXAS) – Nasdaq” on December 21, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: Nasdaq.com and their article: “Notable ETF Outflow Detected – VB, EXAS, ATO, BURL – Nasdaq” published on June 12, 2019 as well as Nasdaq.com‘s news article titled: “Noteworthy Monday Option Activity: GOOG, EXAS, CMG – Nasdaq” with publication date: April 29, 2019.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.